Home > Boards > US OTC > Delisted >

BTG plc (fka BTGGF)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/21/2019 6:29:51 PM - Followers: 0 - Board type: Free - Posts Today: 0

BTG plc 5 Fleet Place London, EC4M 7RD United Kingdom Phone: 44 20 7575 0000 Fax: 44 20 7575 0010 Website: http://www.btgplc.com BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
PostSubject
#2   BTGGF: Acquired. Renee 08/21/19 06:29:51 PM
#1   $BTGGF DD Notes ~ http://www.ddnotesmaker.com/BTGGF stocktrademan 11/29/14 10:48:24 AM
PostSubject